Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Kimia Farma (Persero) Tbk (KAEF.JK)
IDR454.00
+2.00 (+0.44%)
ID JKT Healthcare Medical - Distribution
Address
Jl. Veteran No.9 10110
Jakarta, ID
Jakarta, ID
CEO
Djagad Prakasa Dwialam
Website
kimiafarma.co.id
IPO
2001-07-05
ISIN ID1000070303
Description
PT Kimia Farma (Persero) Tbk, an Indonesian entity, is engaged in the manufacturing and sale of a diverse range of products, including pharmaceuticals, herbal remedies, iodine, salts, quinine and its derivatives, and vegetable oils. Its business operations are structured across several key divisions: Manufacturing, Distribution, Retail, and Other Services. Beyond these, the company's portfolio extends to the production and sale of generic, ethical, licensed, and narcotic pharmaceuticals, along with over-the-counter drugs, medical equipment, raw materials, and cosmetics. Its extensive distribution network ensures products reach various outlets, including pharmacies, hospital pharmacies, medical centers, and drugstores. Established in 1817, the company maintains its headquarters in Jakarta, Indonesia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
IDR454.00
+2.00 (+0.44%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
1.07
Float Shares
277.87M
Free Float %
5.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.44% | -2.83% | +0.42% | -6.80% | -11.11% | -7.69% | -26.72% | -32.87% | -81.54% | -60.00% | +128.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
454.00
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 2 | 0 |
Quality scores
Altman Z-Score
0.07
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Distribution: +5.6%-7.2% Q1'26: -6.3% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+60.2% ★ Q1'26: +172.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-5.3% Q1'26: +3.5% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%-2.7% Q1'26: +2.3% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%-2.7% Q1'26: +2.0% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-5.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×30.03× Q1'26: 13.90× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.86T
est: 5.11T (-5.0%)
|
5.81T
est: 5.69T (+2.1%)
|
6.13T
est: 6.13T (+0.0%)
|
7.45T
est: 7.45T (+0.0%)
|
9.40T
est: 9.19T (+2.3%)
|
10.01T
est: 9.62T (+4.0%)
|
12.86T
est: 10.18T (+26.4%)
|
9.23T
est: 10.94T (-15.6%)
|
9.94T
est: 5.11T (+94.3%)
|
9.22T
est: 5.69T (+62.0%)
|
6.13T
6.13T – 6.13T
+7.6% YoY
|
7.45T
7.45T – 7.45T
+21.7% YoY
|
9.19T
9.19T – 9.19T
+23.2% YoY
|
9.62T
9.62T – 9.62T
+4.7% YoY
|
10.18T
10.18T – 10.18T
+5.8% YoY
|
10.94T
10.94T – 10.94T
+7.5% YoY
|
| EBITDA |
418.84B
est: 164.19B (+155.1%)
|
492.86B
est: 182.79B (+169.6%)
|
608.37B
est: 196.69B (+209.3%)
|
1.16T
est: 239.28B (+385.2%)
|
695.94B
est: 294.88B (+136.0%)
|
914.09B
est: 308.75B (+196.1%)
|
1.39T
est: 326.66B (+326.0%)
|
1.02T
est: 351.13B (+190.4%)
|
-265.60B
est: 97.35B (-372.8%)
|
239.93B
est: 108.38B (+121.4%)
|
116.62B
116.62B – 116.62B
+7.6% YoY
|
141.88B
141.88B – 141.88B
+21.7% YoY
|
174.84B
174.84B – 174.84B
+23.2% YoY
|
183.06B
183.06B – 183.06B
+4.7% YoY
|
193.68B
193.68B – 193.68B
+5.8% YoY
|
208.19B
208.19B – 208.19B
+7.5% YoY
|
| EBIT |
391.05B
est: -14.76B (+2,748.6%)
|
432.78B
est: -16.44B (+2,732.9%)
|
535.66B
est: -17.69B (+3,128.7%)
|
982.52B
est: -21.52B (+4,666.2%)
|
536.29B
est: -26.52B (+2,122.4%)
|
669.74B
est: -27.76B (+2,512.3%)
|
999.70B
est: -29.37B (+3,503.3%)
|
509.21B
est: -31.57B (+1,712.8%)
|
-588.87B
est: -110.76B (-431.7%)
|
-248.17B
est: -123.30B (-101.3%)
|
-132.68B
-132.68B – -132.68B
-7.6% YoY
|
-161.41B
-161.41B – -161.41B
-21.7% YoY
|
-198.92B
-198.92B – -198.92B
-23.2% YoY
|
-208.27B
-208.27B – -208.27B
-4.7% YoY
|
-220.36B
-220.36B – -220.36B
-5.8% YoY
|
-236.86B
-236.86B – -236.86B
-7.5% YoY
|
| Net Income |
248.85B
est: 276.99B (-10.2%)
|
267.41B
est: 293.11B (-8.8%)
|
326.79B
est: 321.83B (+1.5%)
|
415.90B
est: 439.08B (-5.3%)
|
-12.72B
est: 500.04B (-102.5%)
|
17.64B
est: 59.79B (-70.5%)
|
302.27B
est: 104.35B (+189.7%)
|
-190.47B
est: 145.97B (-230.5%)
|
-842.27B
est: 263.02B (-420.2%)
|
-334.96B
est: 278.33B (-220.3%)
|
305.61B
305.61B – 305.61B
+9.8% YoY
|
416.94B
416.94B – 416.94B
+36.4% YoY
|
474.83B
474.83B – 474.83B
+13.9% YoY
|
56.78B
56.78B – 56.78B
-88.0% YoY
|
99.09B
99.09B – 99.09B
+74.5% YoY
|
138.61B
138.61B – 138.61B
+39.9% YoY
|
| SGA |
410.17B
est: 572.88B (-28.4%)
|
506.04B
est: 637.79B (-20.7%)
|
685.97B
est: 686.26B (0.0%)
|
829.03B
est: 834.90B (-0.7%)
|
1.43T
est: 1.03T (+38.5%)
|
1.17T
est: 1.08T (+8.5%)
|
1.03T
est: 1.14T (-9.7%)
|
991.40B
est: 1.23T (-19.1%)
|
1.21T
est: 762.51B (+58.2%)
|
2.79T
est: 848.90B (+228.3%)
|
913.43B
913.43B – 913.43B
+7.6% YoY
|
1.11T
1.11T – 1.11T
+21.7% YoY
|
1.37T
1.37T – 1.37T
+23.2% YoY
|
1.43T
1.43T – 1.43T
+4.7% YoY
|
1.52T
1.52T – 1.52T
+5.8% YoY
|
1.63T
1.63T – 1.63T
+7.5% YoY
|
| EPS |
47.07
est: 47.25 (-0.4%)
|
48.15
est: 50.00 (-3.7%)
|
58.84
est: 54.90 (+7.2%)
|
74.88
est: 74.90 (0.0%)
|
2.86
est: 85.30 (-96.6%)
|
3.18
est: 10.20 (-68.8%)
|
54.42
est: 17.80 (+205.7%)
|
-34.29
est: 24.90 (-237.7%)
|
-151.31
est: 47.25 (-420.2%)
|
-60.17
est: 50.00 (-220.3%)
|
54.90
54.90 – 54.90
+9.8% YoY
|
74.90
74.90 – 74.90
+36.4% YoY
|
85.30
85.30 – 85.30
+13.9% YoY
|
10.20
10.20 – 10.20
-88.0% YoY
|
17.80
17.80 – 17.80
+74.5% YoY
|
24.90
24.90 – 24.90
+39.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-101.94B
OE per share TTM
-18.32
Owner's Yield
-3.82%
Maintenance CapEx ratio
198.11%
Maint CapEx / Avg PPE
95.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-23.17M
Shares Outstanding
5.57B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Budi Her Utomo CPIA | Head of Internal Audit | — | — |
| Disril Revolin Putra | Director of Human Resources & Director | — | male |
| Djagad Prakasa Dwialam | President Director | — | — |
| Eva Fairus | General Manager of Marketing & Sales | — | female |
| Ganti Winarno Putro | General Manager of Corporate Secretary | — | male |
| Hadi Kardoko | Production & Supply Chain and Director & Director | — | male |
| Hanadi Setiarto | Commercial Director & Director | — | male |
| Jasmine K. Karsono | Director of Portfolio, Products & Services and Director | — | female |
| Rosrini | Compliance & Risk Management Unit Manager | — | female |
| Willy Meridian | Finance & Risk Management Director and Director | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KAEF.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
